Chandra Leo
Partner @ HBM Partners
Chandra Leo is a Series B investor at HBM Partners focused on Biotechnology and Health Care. Chandra Leo has over fifteen years of experience in private equity, clinical practice and biomedical research. He is a Former postdoctoral scientist at Stanford University, physician at University Hospital Leipzig and principal at Wellington Partners. He Completed medical studies in Berlin and London, doctoral degree from Freie Universität Berlin(Charité), MBA degree with distinction from INSEAD. He was a board member of Galecto Biotech and Gynesonics, board observer at TP Therapeutics.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Chandra Leo invests in
Stages Chandra Leo invests in
Countries Chandra Leo invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 3 (60%)
- Medical 2 (40%)
- Life Science 2 (40%)
- Health Diagnostics 2 (40%)
Stage
- Series B 2 (40%)
- Series D 2 (40%)
- Series C 1 (20%)
Country
- Israel 1 (20%)
- Denmark 1 (20%)
- Switzerland 1 (20%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $75M / Series D / Aug 23, 2023 | |
Dren Bio
|
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets. | $65M / Series B / Jun 14, 2022 | |
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $64M / Series D / Sep 25, 2020 | |
Monte Rosa Therapeutics
|
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. | $96M / Series B / Sep 24, 2020 | |
|
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $90.2M / Series C / Oct 26, 2018 |
Co-Investors
About HBM Partners
HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.
HBM Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Chandra Leo
Partner
|
|||
Erwin Troxler
CFO
|
|||
Andreas Wicki
Founder & CEO
|
|||
Axel Bolte
Venture Partner
|
|||
Saeid Akhtari
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chandra Leo invest in?
Chandra Leo invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chandra Leo?
Public channels for Chandra Leo include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Chandra Leo last invest?
The most recent investment recorded for Chandra Leo closed in Aug 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
